Brief: Nls Pharmaceutics AG - Announces Patent Issuance In The United States For Its Mazindol Extended-Release Formulation
Brief: Nls Pharmaceutics AG - Announces Final Results From A Preclinical Study For Nls-4 (Lauflumide)
Brief: NLS Pharmaceutics Announces Preclinical Data Demonstrating The Potential Of NLS-4 (Lauflumide) To Treat Chronic Fatigue Associated With Long-Covid
Brief: NLS Pharmaceutics Announces $20 Mln Standby Equity Distribution Agreement
U.S. STOCKS ON THE MOVE-Dlocal, Macy's, Robinhood, NLS Pharma, Ford, Sonoma Pharma
NLS Pharma up on notice of allowance from patent office for ADHD treatment
NLS Pharma gains on FDA nod for narcolepsy drug clinical trial
Brief: NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation For Treating Narcolepsy
Brief: NLS Pharmaceutics Announces Patent Issuance In Europe
Brief: NLS Pharmaceutics Announces Issuance of Canadian Patent Covering Formulation Mazindol CR
NLS Pharma: More than doubles on Novartis license deal
Brief: NLS Pharmaceutics Obtains License To Full Regulatory Data For Sanorex
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:59 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:59 AM
Brief: NLS Pharmaceutics Announces Pricing Of $20.0 Mln Initial Public Offering
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:01 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:59 AM